Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 3;9(1):e002851. doi: 10.1136/rmdopen-2022-002851

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

IL17A peptide vaccine does not mitigate MT-induced SpA in treatment model. (A) Experimental protocol for IL17A vaccination of MT-induced SpA treatment model in HLA-B27 transgenic rats. MT was administered to induce SpA at a week before administration of IL17A vaccine. IL17A vaccine or KLH control was administrated thrice at 2 weeks interval. Blood was collected at 1, 3, 5, 7 and 10 weeks to evaluate the antibody titre. The arthritis score and joint thickness were evaluated every few days. B.C.: blood collection. (B) Antibody titre for IL17A epitope. (C) Body weight was monitored after MT administration. (D) Arthritis score and (E) joint thickness were analysed every 2–3 days to determine the arthritis severity. Data are shown as the mean ± SE error of the mean (SEM). See also online supplemental figure 4.